According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, The biosimilar market reached a value of US$ 7.7 Billion in 2020. Biosimilars, also known as subsequent entry biologics (SEBs) or follow-on biologics, refer to FDA-approved biotherapeutic products which are similar to their reference biologics. Biosimilars can only be manufactured after the patent of the reference product expires. The demand for biosimilars has been increasing in recent years as they help in reducing the overall cost of the treatment for a variety of chronic diseases including cancers, autoimmune diseases, kidney failure, diabetes, CVDs, haematological disorders, infectious diseases, rheumatoid arthritis, growth hormone deficiency, etc.
Request for a PDF sample of this report: https://www.imarcgroup.com/biosimilar-market/requestsample
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Recent patent expiries of a large number of blockbuster biological drugs such as Humira, Remicade, MabThera, Enbrel, etc. have majorly boosted the growth of the biosimilar market. Another major growth-inducing factor is ageing population which has led to a rise in the prevalence of non-communicable diseases. Further, high costs of innovator biologics, especially monoclonal antibodies (mAbs), have encouraged several governments across the globe to promote the usage of biosimilars. For instance, European countries like the Netherlands, Denmark and Germany have established strategic models for discount pricing and introduced numerous incentive programs. Apart from this, biosimilars do not require extensive marketing as the safety and efficacy profile of biologics has already been established. This has resulted into the low cost of these drugs in comparison to their branded counterparts, in turn, spurring their demand worldwide. Catalyzed by these factors, the market is expected to witness strong growth during 2021-2026.
Global Biosimilar Market Summary:
- Based on molecule type, Infliximab represents the largest segment, accounting for the majority of the total market share. Other major categories include Insulin Glargine, Epoetin Alpha, Ethanercept, Filgrastim, Somatropin, Rituximab, and Follitropian Alfa.
- On the basis of the type of manufacturing, the market has been bifurcated into in-house and contract manufacturing. Currently, in-house manufacturing holds around three-fourth of the total share, representing the dominant segment. This method enables the manufacturers to monitor every step of the biosimilars’ production process and eliminates both shipping and delivery costs.
- The market has also been segregated on the basis of indication as autoimmune diseases, oncology, diabetes, a blood disorder, growth deficiency, and female infertility. Amongst these, autoimmune diseases account for around half of the global share.
- Region-wise, Europe is the leading market with more than half of the global share. This can be attributed to the large aging population in the region. Besides Europe, other major regions include the United States, India, Japan, and South Korea.
- On examining the competitive landscape of the market, it has been found that the biosimilars industry is concentrated in nature. Some of the key players operatives in the market are Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Limited, Samsung Biologics, Amgen, Inc., Dr. Reddy’s Laboratories Limited and Stada Arzneimittel Ag.
Competitive Landscape:
- Novartis
- Pfizer
- Teva
- Celltrion
- Merck & Co
- Samsung Bioepis
- Eli Lilly
- Biocon
- Reddy’s Laboratories
- Amgen
- Boehringer Ingelheim
Molecule insights:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Manufacturing Insights:
- In-house Manufacturing
- Contract Manufacturing
Regional Insights:
- United States
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
- South Korea
- Others
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/biosimilar-market
We are updating our reports, If you want the latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, the published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, and nanotechnology industries. We also provide cost model and manufacturing setup project reports through Syndicated Analytics, a subsidiary of IMARC Group.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
